Signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia

References

• Chua SE, McKenna PJ. Schizophrenia ‐ a brain disease? A critical review of structural and functional cerebral abnormality in the disorder. British Journal of Psychiatry 1995; 166: 563–582
   PubMed Web of Science ®Google Scholar
• Stahl S. Psychopharmacology of antipsychotics. Marin Dunitz, London 1999
   Google Scholar
• Carlsson A, Linquist M. Effect of chlorpromazine or haloperidol on formation of 3‐methoxy‐tyramine and normetanephrine in mouse brain. Acta Pharmacologia et Toxicologia 1963; 20: 140–144
   PubMedGoogle Scholar
• Meltzer HY. Biological studies in schizophrenia. Schizophrenia Bulletin 1987; 13: 77–107
   PubMed Web of Science ®Google Scholar
• Bird ED, Spokes EG, Barnes J, Mackay AVP, Iversen LL, Shepherd M. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet 1977; ii: 1157–1159
   Google Scholar
• Reynolds GP. Increased concentrations and lateral asymmetries of amygdala dopamine in schizophrenia. Nature 1983; 305: 527–529
   PubMed Web of Science ®Google Scholar
• Toru M, Nishikawa T, Mataga N, Tashima M. Dopamine metabolism increases in post‐mortem schizophrenic basal ganglia. Journal of Neural Transmission 1982; 54: 181–191
   PubMedGoogle Scholar
• Beskow J, Gottfries CG, Roos BE, Winblad B. Determination of monoamine and monoamine metabolites in the human brain: post mortem studies in a group of suicides and in a control group. Acta Psychiatrica Scandinavica 1976; 53: 7–20
   PubMed Web of Science ®Google Scholar
• Bachus SE, Kleinman JE. The neuropathology of schizophrenia. Journal of Clinical Psychiatry 1996; 57(Suppl. 11)72–83
   PubMedGoogle Scholar
• Reynolds GP, Reynolds LM, Riederer P, Jellinger K, Gabriel E. Dopamine receptors and schizophrenia: drug effect or illness. Lancet 1980; i: 1251
   Google Scholar
• Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979; 277: 93–96
   PubMed Web of Science ®Google Scholar
• Sibley DR, Monsma FJ. Molecular biology of dopamine receptors. Trends in Pharmacological Sciences 1992; 13: 61–69
   PubMed Web of Science ®Google Scholar
• Roberts DA, Balderson D, Pickering‐Brown SM, Deakin JFW, Owen F. The abundance of mRNA for dopamine D2 receptor isoforms in brain tissue from controls and schizophrenics. Brain Research: Molecular Brain Research 1994; 25: 173–175
   PubMedGoogle Scholar
• Van Tol HHM, Bunzow JR, Guan H‐C, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610–614
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. New England Medical Journal 1991; 324: 746–754
   PubMed Web of Science ®Google Scholar
• Meador‐Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex ‐ focal abnormalities in orbitofrontal cortex in schizophrenia. Archives of General Psychiatry 1997; 54: 1089–1095
   PubMedGoogle Scholar
• Dean B, Pavey G, Opeskin K. [3H]raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects. Neuropharmacology 1997; 36: 779–786
   PubMedGoogle Scholar
• Stefanis NC, Bresnick JN, Kerwin RW, Schofield WN, McAllister G. Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain. Brain Research: Molecular Brain Research 1998; 53: 112–119
   PubMedGoogle Scholar
• Mulcrone J, Kerwin RW. No difference in the expression of the D4 gene in post‐mortem frontal cortex from controls and schizophrenics. Neuroscience Letters 1996; 219: 163–166
   PubMed Web of Science ®Google Scholar
• Schmauss C, Haroutunian V, Davis KL, Davidson M. Selective loss of dopamine D3‐type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 1993; 90: 8942–8946
   PubMed Web of Science ®Google Scholar
• Gilbert DB, Millar J, Cooper SJ. The putative dopamine D3 agonist, 7‐OH‐DPAT, reduces dopamine release in the nucleus accumbens and electrical self‐stimulation to the ventral tegmentum. Brain Research 1995; 681: 1–7
   PubMed Web of Science ®Google Scholar
• Meller E, Bohmaker K, Goldstein M, Basham DA. Evidence that striatal synthesis‐inhibiting autoreceptors are dopamine D3 receptors. European Journal of Pharmacology 1993; 249: R5–R6
   Google Scholar
• Clark D, Hjorth S, Carlsson A. Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II: theoretical considerations. Journal of Neural Transmission 1985; 62: 171–207
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi‐Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine‐induced dopamine release in drug‐free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 9235–9240
   PubMed Web of Science ®Google Scholar
• Breier A, Su TP, Saunders R, Carson RE, et al. Schizophrenia is associated with elevated amphetamine‐induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America 1997; 94: 2569–2574
   PubMed Web of Science ®Google Scholar
• Huttunen M. The evolution of the serotonin‐dopamine antagonist concept. Journal of Clinical Psychopharmacology 1995; 15(Suppl. 1)4S–10S
   Google Scholar
• Bennett JP, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH. Neurotransmitter receptors in frontal cortex of schizophrenics. Archives of General Psychiatry 1979; 36: 927–934
   PubMed Web of Science ®Google Scholar
• Whitaker PM, Crow TJ, Ferrier IN. Tritiated LSD binding in frontal cortex in schizophrenia. Archives of General Psychiatry 1981; 38: 278–280
   PubMed Web of Science ®Google Scholar
• Mita T, Hanada S, Nishino N, et al. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biological Psychiatry 1986; 21: 1407–1414
   PubMed Web of Science ®Google Scholar
• Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biological Psychiatry 1997; 42: 529–545
   PubMed Web of Science ®Google Scholar
• Dean B, Hayes W, Hill C, Copolov D. Decreased serotonin 2A receptors in Brodmann's area 9 from schizophrenic subjects. A pathological or pharmacological phenomenon?. Molecular and Chemical Neuropathology 1998; 34: 133–145
   PubMedGoogle Scholar
• Burnet PW, Eastwood SL, Harrison PJ. 5‐HT1A and 5‐HT2A receptor mRNA and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996; 15: 442–455
   PubMed Web of Science ®Google Scholar
• Lewis R, Kapur S, Jones C, et al. Serotonin 5‐HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic‐naive patients and normal subjects. American Journal of Psychiatry 1999; 156: 72–78
   PubMed Web of Science ®Google Scholar
• Trichard C, Paillere‐Martinot ML, Attar‐Levy D, Blin J, Feline A, Martinot JL. No serotonin 5‐HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophrenia Research 1998; 31: 13–17
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5‐HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sciences 1991; 48: 355–363
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi‐Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: a postmortem study. Archives of General Psychiatry 1993; 50: 810–818
   PubMed Web of Science ®Google Scholar
• Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY. Serotonin 1A receptors are increased in post‐mortem prefrontal cortex in schizophrenia. Brain Research 1996; 708: 209–214
   PubMed Web of Science ®Google Scholar
• Simpson MDC, Lubman DI, Slater P, Deakin JFW. Autoradiography with [3H]8‐OH‐DPAT reveals increases in 5‐HT1A receptors in ventral prefrontal cortex in schizophrenia. Biological Psychiatry 1996; 39: 919–928
   PubMed Web of Science ®Google Scholar
• Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993; 8: 315–336
   PubMed Web of Science ®Google Scholar
• Dean B, Tomaskovic‐Crook E, Opeskin K, Keks N, Copolov D. No change in the density of the serotonin 1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. Neurochemistry International 1999; 34: 109–115
   PubMedGoogle Scholar
• Hashimoto T, Kitamura N, Kajimoto Y, et al. Differential changes in serotonin 5‐HT1A and 5‐HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology 1993; 112: S35–S39
   Web of Science ®Google Scholar
• Dean B, Opeskin K, Pavey G, et al. [3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. Journal of Neurochemistry 1995; 64: 1197–1202
   PubMed Web of Science ®Google Scholar
• Naylor L, Dean B, Opeskin K, et al. Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine. Journal of Neural Transmission 1996; 103: 749–757
   PubMed Web of Science ®Google Scholar
• Naylor L, Dean B, Pereira A, Mackinnon A, Kouzmenko A, Copolov D. No association between the serotonin transporter‐linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus. Molecular Medicine 1998; 4: 671–674
   PubMedGoogle Scholar
• Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. A ‘glutamate hypothesis’ of schizophrenia. Clinical Neuropharmacology 1989; 12: 1–13
   PubMed Web of Science ®Google Scholar
• Javitt DC. Negative symptoms and the PCP (phencyclidine) model of schizophrenia. Hillside Journal of Clinical Psychiatry 1987; 9: 12–35
   PubMedGoogle Scholar
• Simpson MDC, Slater P, Royston MC, Deakin JFW. Alterations in phencyclidine and sigma binding sites in schizophrenic brain. Schizophrenia Research 1992; 6: 41–48
   Google Scholar
• Dean B, Scarr E, Bradbury R, Copolov D. Decreased hippocampal (CA3) NMDA receptors in schizophrenia. Synapse 1999; 32: 67–69
   PubMedGoogle Scholar
• Aparicio‐Legarza MI, Davis B, Hutson PH, Reynolds GP. Increased density of glutamate/N‐methyl‐D‐aspartate receptors in putamen from schizophrenic patients. Neuroscience Letters 1998; 241: 143–146
   PubMedGoogle Scholar
• Kornhuber J, Mack‐Burkhardt F, Riederer P, et al. [3H]MK‐801 binding sites in postmortem brain regions of schizophrenic patients. Journal of Neural Transmission 1989; 77: 231–236
   PubMed Web of Science ®Google Scholar
• Noga JT, Hyde TM, Herman MM, et al. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse 1997; 27: 168–176
   PubMed Web of Science ®Google Scholar
• Grimwood S, Slater P, Deakin JF, Hutson PH. NR2B‐containing NMDA receptors are up‐regulated in temporal cortex in schizophrenia. Neuroreport 1999; 10: 461–465
   PubMedGoogle Scholar
• Collingridge GL, Lester RAJ. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacological Reviews 1989; 40: 145–210
   Google Scholar
• Nishikawa T, Takashima M, Toru M. Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neuroscience Letters 1983; 40: 245–250
   PubMed Web of Science ®Google Scholar
• Deakin JFW, Slater P, Simpson MDC, et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. Journal of Neurochemistry 1989; 52: 1781–1786
   PubMed Web of Science ®Google Scholar
• Toru M, Watanabe S, Shibuya H, et al. Neurotransmitter, receptors and neuropeptides in post‐mortem brains of chronic schizophrenic patients. Acta Psychiatrica Scandinavica 1988; 78: 121–137
   PubMed Web of Science ®Google Scholar
• Kerwin RW, Patel S, Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 1990; 39: 25–32
   PubMed Web of Science ®Google Scholar
• Kurumaji A, Ishimaru M, Toru M. α‐[3H]amino‐3‐hydroxy‐5‐methylisoxazole‐4‐propionic acid binding to human cerebral cortical membranes: minimal changes in postmortem brains of chronic schizophrenics. Journal of Neurochemistry 1992; 59: 829–837
   PubMedGoogle Scholar
• Seeburg PH. The TINS/TiPS lecture: The molecular biology of mammalian glutamate receptor channels. Trends in Pharmacological Sciences 1993; 16: 359–365
   Google Scholar
• Humphries C, Mortimer A, Hirsch S, De Belleroche J. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport 1996; 7: 2051–2055
   PubMedGoogle Scholar
• Sokolov BP. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of ‘neuroleptic‐free’ schizophrenics: evidence on reversible up‐regulation by typical neuroleptics. Journal of Neurochemistry 1998; 71: 2454–2464
   PubMedGoogle Scholar
• Akbarian S, Sucher NJ, Bradley D, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. Journal of Neuroscience 1996; 16: 19–30
   PubMedGoogle Scholar
• Harrison PJ, McLaughlin D, Kerwin RW. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 1991; 337: 450–452
   PubMed Web of Science ®Google Scholar
• Porter RHP, Eastwood SL, Harrison PJ. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Research 1997; 751: 217–231
   PubMedGoogle Scholar
• Eastwood SL, Burnet PW, Harrison PJ. GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: a reverse transcriptase‐polymerase chain reaction (RT‐PCR) study. Brain Research: Molecular Brain Research 1997; 44: 92–98
   PubMedGoogle Scholar
• Eastwood SL, Kerwin RW, Harrison PJ. Immunoautoradiographic evidence for a loss of alpha‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionate‐preferring non‐N‐methyl‐D‐aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biological Psychiatry 1997; 41: 636–643
   PubMedGoogle Scholar
• Bartha R, Williamson PC, Drost DJ, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never‐treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Archives of General Psychiatry 1997; 54: 959–965
   PubMed Web of Science ®Google Scholar
• Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6: 869–872
   PubMed Web of Science ®Google Scholar
• Simpson MDC, Slater P, Royston MC, Deakin JFW. Regionally selective deficits in uptake sites for glutamate and gamma‐aminobutyric acid in the basal ganglia of schizophrenics. Psychiatry Research 1992; 42: 273–282
   PubMedGoogle Scholar
• Aparicio‐Legarza MI, Cutts AJ, Davis B, Reynolds GP. Deficits of [3H]D‐aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia. Neuroscience Letters 1997; 232: 13–16
   PubMed Web of Science ®Google Scholar
• van Kammen DP. γ‐Aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia. American Journal of Psychiatry 1977; 134: 138–143
   PubMed Web of Science ®Google Scholar
• Perry TL, Buchanan J, Kish SJ, Hansen S. γ‐aminobutyric‐acid deficiency in brain of schizophrenic patients. Lancet 1979; i: 237–239
   Google Scholar
• Mhatre MC, Ticku MK. Chronic GABA treatment downregulates the GABAA receptor alpha 2 and alpha 3 subunit mRNAS as well as polypeptide expression in primary cultured cerebral cortical neurons. Brain Research Molecular Brain Research 1994; 24: 159–165
   PubMedGoogle Scholar
• Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenia. Journal of Neuroscience 1992; 12: 924–929
   PubMedGoogle Scholar
• Benes FM, Vincent SL, Marie A, Khan Y. Up‐regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 1996; 75: 1021–1031
   PubMed Web of Science ®Google Scholar
• Dean B, Hussain T, Hayes W, et al. Changes in serotonin2A and GABA (A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. Journal of Neurochemistry 1999; 72: 1593–1599
   PubMed Web of Science ®Google Scholar
• Benes FM, Khan Y, Vincent SL, Wickramasinghe R. Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse 1996; 22: 338–349
   PubMedGoogle Scholar
• Kiuchi Y, Kobayashi T, Takeuchi J, Shimizu H, Ogata H, Toru M. Benzodiazepine receptors increase in post‐mortem brain of chronic schizophrenics. European Archives of Psychiatry and Neurological Science 1989; 239: 71–78
   PubMedGoogle Scholar
• Reynolds GP, Stroud D. Hippocampal benzodiazepine receptors in schizophrenia. Journal of Neural Transmission (General Section) 1993; 93: 151–155
   PubMedGoogle Scholar
• Pandey GN, Conley RR, Pandey SC, et al. Benzodiazepine receptors in the post‐mortem brain of suicide victims and schizophrenic subjects. Psychiatry Research 1997; 71: 137–149
   PubMedGoogle Scholar
• Squires RF, Lajtha A, Saederup E, Palkovits M. Reduced [3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective glutamatergic neurons associated with major psychosis?. Neurochemical Research 1993; 18: 219–223
   PubMedGoogle Scholar
• Akbarian S, Huntsman MM, Kim JJ, et al. GABAA receptor subunit gene expression in human prefrontal cortex. Comparison of schizophrenics and controls. Cerebral Cortex 1995; 5: 550–560
   PubMed Web of Science ®Google Scholar
• Huntsman MM, Tran BV, Potkin SG, Bunney WE, Jr, Jones EG. Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma‐amino butyrate type A receptor in prefrontal cortex of schizophrenics. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 15066–15071
   PubMed Web of Science ®Google Scholar
• Busatto GF, Pilowsky LS, Costa DC, et al. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. American Journal of Psychiatry 1997; 154: 56–63
   PubMed Web of Science ®Google Scholar
• Ball S, Busatto GF, David AS, et al. Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I‐Iomazenil SPET study. Biological Psychiatry 1998; 43: 107–117
   PubMed Web of Science ®Google Scholar
• Schroder J, Bubeck B, Demish S, Sauer H. Benzodiazepine receptor distribution and diazepam binding in schizophrenia: an exploratory study. Psychiatry Research 1997; 68: 125–131
   PubMedGoogle Scholar
• Simpson MDC, Slater P, Deakin JFW, Royston MC, Skan WJ. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neuroscience Letters 1989; 107: 211–215
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Czudek C, Andrews HB. Deficit and hemispheric asymmetry of GABA uptake sites in hippocampus in schizophrenia. Biological Psychiatry 1990; 27: 1038–1044
   PubMed Web of Science ®Google Scholar
• Woo T‐U, Miller JL, Lewis DA. Schizophrenia and the parvalbumin‐containing class of cortical local circuit neurons. American Journal of Psychiatry 1997; 154: 1013–1015
   PubMed Web of Science ®Google Scholar
• Akbarian S, Kim JJ, Potkin SG, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Archives of General Psychiatry 1995; 52: 258–266
   PubMed Web of Science ®Google Scholar
• Tandon R. Cholinergic aspects of schizophrenia. British Journal of Psychiatry 1999; 37(Suppl.)7–11
   Google Scholar
• Sarter M, Bruno JP. Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Trends in Neuroscience 1999; 22: 67–74
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Beasley CM, Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 1997; 154: 457–465
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87–96
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. Possible changes in striatal and limbic cholinergic systems in schizophrenia. Archives of General Psychiatry 1977; 34: 1319–1323
   PubMed Web of Science ®Google Scholar
• Domino EF, Krause RR, Bowers J. Various enzymes involved with putative neurotransmitters. Archives of General Psychiatry 1973; 29: 195–201
   PubMed Web of Science ®Google Scholar
• Karson GN, Casanova MF, Kleinman JE, Griffin WST. Choline acetyltransferase in schizophrenia. American Journal of Psychiatry 1993; 150: 454–459
   PubMed Web of Science ®Google Scholar
• Watanabe S, Nishikawa T, Takashima M, Toru M. Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sciences 1983; 33: 2187–2196
   PubMed Web of Science ®Google Scholar
• Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL. The density of muscarinic M1 receptors is decreased in the caudate‐ putamen of subjects with schizophrenia. Molecular Psychiatry 1996; 1: 54–58
   PubMed Web of Science ®Google Scholar
• Dean B, Crook JM, Pavey G, Opeskin K, Copolov DL. Studies on M1 and M2 muscarinic receptor mRNA in the human caudate‐putamen: no change in M1 receptor mRNA in schizophrenia. Molecular Psychiatry 2000; 5: 203–207
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders4th edn. American Psychiatric Association, Washington 1994
   Google Scholar
• Marsh M, McMahon HT. The structural era of endocytosis. Science 1999; 285: 215–220
   PubMed Web of Science ®Google Scholar